Updates on cardiovascular outcome trials in diabetes
نویسندگان
چکیده
In 2008 the Food and Drug Administration introduced a guidance for industry that requires the investigation of cardiovascular outcomes of glucose-lowering medications. Since then, an increasing number of cardiovascular outcome trials have been completed in diabetes patients with high cardiovascular risk for members of the SGLT-2 and DPP4 inhibitors and GLP-1 receptor agonist classes. The trials confirmed cardiovascular safety for all tested anti-hyperglycaemic drugs and, in addition empagliflozin, semaglutide and liraglutide could even reduce cardiovascular risk. The present review summarizes the results of the DEVOTE, CANVAS, EXSCEL and ACE trials that tested cardiovascular safety of Insulin degludec, canagliflozin, once-weekly exenatide and acarbose and were published in 2017. We provide context on these results by comparing them with earlier trials of glucose-lowering drugs and give an outlook on what to expect in coming years.
منابع مشابه
Correction to: Updates on cardiovascular outcome trials in diabetes
Following publication of the original article [1], the authors submitted a corrected version of Table 4 (see below).
متن کاملCardiovascular outcome trials in type 2 diabetes: what have we learned from the past and present?
There is a wealth of epidemiological data which shows that type 2 diabetes significantly increase the risk of cardiovascular events. The evidence from earlier trials have demonstrated that improvement in glycated haemoglobin will reduce the risk of micro vascular disease but there is lack of robust evidence to suggest whether improvement in glycaemic control will have similar beneficial outcome...
متن کاملOptimizing the analysis strategy for the CANVAS Program: A prespecified plan for the integrated analyses of the CANVAS and CANVAS‐R trials
Two large cardiovascular outcome trials of canagliflozin, comprising the CANVAS Program, will complete in early 2017: the CANagliflozin cardioVascular Assessment Study (CANVAS) and the CANagliflozin cardioVascular Assessment Study-Renal (CANVAS-R). Accruing data for the sodium glucose co-transporter 2 (SGLT2) inhibitor class has identified questions and opportunities that were not apparent when...
متن کاملFollow the LEADER—Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results Trial
This commentary analyzes the Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER) trial, which has reported the cardiovascular benefits of liraglutide. It places the results of this seminal trial in the context of the evolution of diabetes care, compares them with other recently published cardiovascular outcome trials, and suggests novel mechanisms to...
متن کاملAssociation of the FDA Amendment Act with trial registration, publication, and outcome reporting
BACKGROUND Selective clinical trial publication and outcome reporting has the potential to bias the medical literature. The 2007 Food and Drug Administration (FDA) Amendment Act (FDAAA) mandated clinical trial registration and outcome reporting on ClinicalTrials.gov, a publicly accessible trial registry. METHODS Using publicly available data from ClinicalTrials.gov, FDA documents, and PubMed,...
متن کامل